United Capital Financial Advisors LLC Buys Shares of 19,972 Edwards Lifesciences Corporation $EW

United Capital Financial Advisors LLC purchased a new position in Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, HoldingsChannel reports. The institutional investor purchased 19,972 shares of the medical research company’s stock, valued at approximately $1,807,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Rehmann Capital Advisory Group lifted its holdings in shares of Edwards Lifesciences by 2.1% during the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock worth $546,000 after acquiring an additional 130 shares during the last quarter. McIlrath & Eck LLC increased its stake in Edwards Lifesciences by 14.6% in the fourth quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company’s stock valued at $90,000 after acquiring an additional 135 shares during the last quarter. Quadrant Capital Group LLC raised its position in Edwards Lifesciences by 0.9% during the fourth quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company’s stock valued at $1,288,000 after purchasing an additional 136 shares in the last quarter. Stephens Inc. AR lifted its stake in Edwards Lifesciences by 5.4% during the fourth quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company’s stock worth $239,000 after purchasing an additional 144 shares during the last quarter. Finally, Composition Wealth LLC increased its position in shares of Edwards Lifesciences by 1.6% during the 4th quarter. Composition Wealth LLC now owns 9,331 shares of the medical research company’s stock valued at $795,000 after purchasing an additional 147 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Bruls sold 2,644 shares of the company’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the transaction, the vice president owned 17,984 shares of the company’s stock, valued at $1,618,200.32. This trade represents a 12.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 4,501 shares of company stock valued at $408,213 in the last ninety days. 0.31% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on EW. Citigroup upped their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. UBS Group started coverage on shares of Edwards Lifesciences in a report on Tuesday, July 28th. They set a “buy” rating and a $110.00 target price on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. Piper Sandler reaffirmed an “overweight” rating and set a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Finally, Evercore reissued an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a research note on Monday, July 6th. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Trading Up 0.3%

Shares of EW opened at $90.19 on Friday. The stock has a market capitalization of $51.93 billion, a P/E ratio of 51.83, a PEG ratio of 2.37 and a beta of 0.85. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The firm has a fifty day simple moving average of $89.54 and a two-hundred day simple moving average of $85.03.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. Edwards Lifesciences’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.